Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Libro |
| Publicado: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Materias: | |
| Acceso en línea: | Connect to this object online. |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Internet
Connect to this object online.3rd Floor Main Library
| Número de Clasificación: |
A1234.567 |
|---|---|
| Copia 1 | Disponible |